SecBot SecBot

TNGX

Tango Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001819133 Biotech & Drug Discovery
$24.17 −1.33 (−5.22%)
Nov 16 4:00 PM ET · prev $25.50
Market cap
$4.2B
Mid cap
Consensus
Buy
89% Buy or better · 19 analysts
Median target
$46.00
+90% · range $24.00–68.00
1 year
+202.9%
from $7.98 · Nov 17
30 days
+2.7%
from $23.53
52-week range
$7.98–32.90
−27% from high · low Nov 17
Avg volume 20D
4.18M
Oct 23 spike 15.85M
Short interest
48.24M
≈28.6% of shares · +7.7%
Days to cover
9.7
at average volume
Insider net
−$7.4M
0 buyers · 3 sellers · since Feb 3
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
25
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 2 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $7.4M.

  • InstitutionsBULLISH

    Q3 2026: 34 added (0 new), 19 trimmed or exited.

  • AnalystsBULLISH

    17 of 19 rate it Buy or better. Median target $46.00 (+90%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.330 → −$0.351 over 90 days. 1 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +7.7% to 48.24M shares. 9.7 days to cover, ≈28.6% of shares.

  • TrendUPTREND

    3% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 23.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCADD1,282,785$32.0M
Fisher Asset Management, LLCADD1,068,505$26.7M
Connor, Clark & Lunn Investment Management Ltd.ADD838,059$20.9M
Jefferies Financial Group Inc.TRIM627,609$15.7M
UBS Group AGADD601,945$15.0M
Assenagon Asset Management S.A.ADD595,912$14.9M
Candriam S.C.A.TRIM477,921$12.0M
CONGRESS ASSET MANAGEMENT COADD478,454$11.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 89% rate it Buy or better
Strong Buy9Buy8Hold2Sell0Strong Sell0
12-month targets · 11 analysts

Price is inside the target range. Median implies +90%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Nov 10, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Nov 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 29, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 16, 2026William Blair
INITIATE
INITIATEOutperform
Aug 18, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$7.4M
sold · 3 insiders
DateInsiderTypeValue
Nov 11, 2026
Crystal Adam
President, R&D
Nov 11, 2026
EXERCISE$14.6K
Nov 11, 2026
Crystal Adam
President, R&D
Nov 11, 2026
SELL$125.0K
Nov 2, 2026
Crystal Adam
President, R&D
Nov 2, 2026
SELL$25.3K
Nov 2, 2026
Crystal Adam
President, R&D
Nov 2, 2026
SELL$86.8K
Nov 2, 2026
Crystal Adam
President, R&D
Nov 2, 2026
EXERCISE$14.6K
Nov 2, 2026
Newcomb Jessica
Principal Accounting Officer
Nov 2, 2026
SELL$33.6K
Nov 2, 2026
Newcomb Jessica
Principal Accounting Officer
Nov 2, 2026
SELL$124.1K
Oct 1, 2026
Crystal Adam
President, R&D
Oct 1, 2026
SELL$645.6K

Earnings setup

Estimates
−$0.35
EPS estimate, this quarter
−6%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.35-$0.42–-$0.30+0.1%$0.00
Next Q-$0.43-$0.50–-$0.33-13.9%$1.1M
Current FY-$1.46-$1.63–-$1.14-4.3%$0.00
Next FY-$1.80-$2.36–-$1.24-6.7%$2.6M
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
48,239,154
shares short
+7.7%
vs prior settlement
9.7
days to cover
≈28.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 11, 2026 Insider
Crystal Adam acquired via exercise 5,000 shares
President, R&D @ $2.91 ($14.6K)
Nov 11, 2026 Insider
Crystal Adam sold 5,000 shares
President, R&D @ $25.00 ($125.0K)
Nov 10, 2026 Earnings calendar
TNGX Q3 2026 Earnings Scheduled · 2026-11-10
Nov 9, 2026 SEC
Tango Therapeutics reported Q3 2026 net loss of $68.4M ($0.39/share) vs net income of $15.9M ($0.14/share) in Q3 2025…
PRESS-RELEASE · Impact 5/10
Nov 2, 2026 Insider
Crystal Adam sold 1,100 shares
President, R&D @ $22.99 ($25.3K)
Sep 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC · ADD
1,282,785 shares ($32.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 10, 2026
Earnings date
TNGX Q3 2026 Earnings Scheduled · 2026-11-10
Nov 9, 2026
Earnings
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective…
Sep 3, 2026
Press release
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that…
Sep 1, 2026
Press release
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that…
Aug 12, 2026
Earnings date
TNGX Q2 2026 Earnings Scheduled, 2026-08-12

SecBot reports

25 filings · 2 press releases · 6 bullish · 4 bearish · 2 mixed · 13 neutral
All TNGX filing & press-release reports (27)